Thalidomide-O-amido-C6-NH2 TFA

Cat. No.: HY-112618A

CAS No.: 1950635-14-9

Molecular Formula: $C_{23}H_{27}F_3N_4O_8$

Molecular Weight: 544.48

Target: E3 Ligase Ligand-Linker Conjugates

Pathway: PROTAC

Storage: 4°C, stored under nitrogen

* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (183.66 mM; Need ultrasonic)

Preparing Stock Solutions	Concentration / Solvent / Mass	1 mg	5 mg	10 mg
	1 mM	1.8366 mL	9.1831 mL	18.3661 mL
	5 mM	0.3673 mL	1.8366 mL	3.6732 mL
	10 mM	0.1837 mL	0.9183 mL	1.8366 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 5 mg/mL (9.18 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 5 mg/mL (9.18 mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 5 mg/mL (9.18 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Thalidomide-O-amido-C6-NH2 TFA (Cereblon Ligand-Linker Conjugates 11 TFA), a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker, can be used in the synthesis of PROTACs[1].

IC_{50} & Target

Cereblon

In Vitro

PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Bradner J, et al. Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses. WO 2017024318 A1

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA